Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

BIFANG: A Multicentre, Single-Arm, Phase 3b Study to Assess Nasal Polyps Score and Symptoms in Chinese Adult Participants With Chronic Rhinosinusitis With Nasal Polyposis Initiating Treatment With Tezepelumab

NCT07520162 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT07520162
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07520162 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
BIFANG: A Multicentre, Single-Arm, Phase 3b Study to Assess Nasal Polyps Score and Symptoms in Chinese Adult Participants With Chronic Rhinosinusitis With Nasal Polyposis Initiating Treatment With Tezepelumab
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Recruiting
Start date
April 24, 2026
Completion date
March 7, 2028
Enrollment
230 (estimated)
Sites
48

Conditions

As the registry lists them; a condition with its own page is linked.

chronic rhinosinusitis with nasal polyps